Table I.
Patient demographics, medical history, and disease characteristics (N=23 patients).
| Demographics | Value | (%) (range) |
|---|---|---|
| Gender (N) | ||
| Male | 12 | 52.2 |
| Female | 11 | 47.8 |
| Age (years) | ||
| Mean ± SD | 16.1±4.4 | (9–26) |
| Median | 16.0 | |
| Male | ||
| Mean ± SD | 17.7±5.0a | (10–26) |
| Median | 17 | |
| Female | ||
| Mean ± SD | 13.5±3.1a | (9–18) |
| Median | 14 | |
| Tumor site (N)b | ||
| Distal femur | 8 | (34.8) |
| Proximal tibia | 6 | (26.1) |
| Distal humerus | 3 | (13.0) |
| Proximal humerus | 3 | (13.0) |
| Pelvis | 1 | (4.3) |
| Clavicle | 2 | (8.7) |
| Enneking grade (N) | ||
| IIB | 21 | (91.3) |
| III | 2 | (8.7) |
| Type of OS (N) | ||
| Conventional OS | 21 | (91.3) |
| Small round-cell OS | 2 | (8.7) |
| Pathological fracture (N) | ||
| Yes | 1 | (4.3) |
| No | 22 | (95.7) |
| Alkaline phosphatase (N) | ||
| Elevated | 17 | (73.9) |
| Normal (male 45–125 IU/l; female 35–100 IU/l) | 6 | (26.1) |
| Male, mean ± SD (IU/l) | 169±54 | (87–314) |
| Female, mean ± SD (IU/l) | 148±87 | (66–340) |
| Treatment of primary tumor (N) | ||
| Neoadjuvant chemotherapy | ||
| Yes | 23 | (100.0) |
| No | 0 | (0.0) |
| Surgery | ||
| Amputation | 0 | (0.0) |
| Limb salvage | 23 | (100.0) |
| Postoperative chemotherapy | ||
| Yes | 23 | (100.0) |
| No | 0 | (0.0) |
| Recurrence or metastasis (N) | ||
| Yes | 13 | (56.5) |
| No | 10 | (43.5) |
| Site of recurrence or metastasis (N) | ||
| Primary tumor site | 3c | (23.1) |
| Lung | 13 | (100.0) |
| Other | 1d | (7.7) |
| Treatment of recurrent or metastatic tumor (N) | 12 | (92.3) |
| Chemotherapy | 6 | (46.2) |
| Surgery and chemotherapy | 3 | (23.1) |
| Gamma knife and chemotherapy | 2 | (15.4) |
| Surgery and gamma knife and chemotherapy | 1 | (7.7) |
| Mortality within the follow-up period (N) | ||
| Alive | 18 | (78.3) |
| Deceased | 5 | (21.7) |
| Progression-free survival (weeks, N=23) | ||
| Mean | 100.2 | |
| SD | 69.5 | |
| Median | 77.0 |
a
P=0.029 based on a two-tailed homoscedastic Student's t-test.
b
One patient had two primary OS sites, namely distal femur and proximal tibia, as a result of which there were 24 tumor sites in total.
c
All 3 patients also had lung metastases.
d
Patient had metastasis to lung and distal end of primary tumor site (proximal tibia).